Aetna modified CPB 0763 for homocysteine testing (CPT 83090), effective November 14, 2025. Here's what billing teams need to do.
Aetna updated its homocysteine testing coverage policy under CPB 0763. The policy now explicitly covers four specific indications and lists over 40 uses as experimental, investigational, or unproven. If your billing team submits CPT 83090 for cardiovascular risk screening, Alzheimer's assessment, or MTHFR management, expect claim denials—those uses are explicitly listed as unproven. The four approved indications remain narrow and specific, and your ICD-10 pairing has to match precisely.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Homocysteine Testing |
| Policy Code | CPB 0763 |
| Change Type | Modified |
| Effective Date | November 14, 2025 |
| Impact Level | High |
| Specialties Affected | Hematology, Neurology, Ophthalmology, Internal Medicine, Obstetrics, Genetics, Nephrology |
| Key Action | Audit all CPT 83090 claims and confirm each maps to one of four covered indications with a matching, compliant ICD-10 code |
Aetna Homocysteine Testing Coverage Criteria and Medical Necessity Requirements 2025
The Aetna homocysteine testing coverage policy is built around four specific clinical scenarios. Outside those four, you're not getting paid—and Aetna is explicit about it.
Aetna considers CPT 83090 (plasma homocysteine measurement) medically necessary for:
| # | Covered Indication |
|---|---|
| 1 | Borderline vitamin B12 deficiency — but only when the result will directly change how the member is managed. A fishing expedition won't qualify. If the physician documents that the result will inform treatment decisions, you have a shot at medical necessity. |
| 2 | Central retinal vein occlusion — covered when the member has a personal history of thrombosis, a family history of thrombosis, or is under 56 years old without clear arteriosclerotic risk factors. All three conditions have their own ICD-10 paths, so your diagnosis pairing matters. |
| 3 | Homocystinuria from cystathionine beta synthase deficiency — covered for assessment. For newborn screening specifically, plasma homocysteine measurements are only covered after hypermethioninemia has been confirmed. Don't bill 83090 as the first-line newborn test. |
| 4 | Idiopathic or recurrent venous thromboembolism, thrombosis under age 45, or thrombosis at an unusual site — the age threshold of 45 is a hard line. Document the member's age at time of thrombosis. |
Prior authorization requirements are not explicitly detailed in CPB 0763, but given the narrow indications and the breadth of the exclusion list, your billing guidelines should include a clinical documentation review before submitting. If you're unsure whether a specific member's presentation qualifies, loop in your compliance officer before the claim goes out.
The reimbursement risk here is real. CPT 83090 is a single-code test with a relatively low unit cost, but volume makes it meaningful. If your practice runs homocysteine panels as part of broader metabolic workups—particularly for cardiovascular risk stratification—those claims will not survive Aetna's medical necessity review under this coverage policy.
Aetna Homocysteine Testing Exclusions and Non-Covered Indications
This is where CPB 0763 gets long. Aetna lists over 40 specific uses as experimental, investigational, or unproven. The list makes clear that Aetna has reviewed the evidence for these uses and found it insufficient—not just absent.
The most billing-relevant exclusions are the ones your physicians are most likely to order:
| # | Excluded Procedure |
|---|---|
| 1 | Cardiovascular disease or stroke risk assessment — this is the big one. Many providers order homocysteine as a cardiac risk marker. Aetna says no, and points to CPB 0381 for that conversation. |
| 2 | Cognitive impairment and dementia (including Alzheimer's disease) — popular in neurology and geriatrics workups. Not covered. |
| 3 | MTHFR gene variant management — a common functional medicine ordering pattern. Aetna explicitly excludes management of 5,10-methylenetetrahydrofolate reductase abnormalities. |
| 4 | Monitoring methotrexate therapy — rheumatology teams should note this. Homocysteine is not a covered monitoring tool under this policy. |
| 5 | Recurrent pregnancy loss — points to CPB 0348 instead. |
| 6 | Depression, including suicide risk prediction — excluded. |
| 7 | Migraine headaches — excluded. |
| 8 | Multiple sclerosis — excluded. |
| 9 | Pre-eclampsia risk — excluded. |
| 10 | IVF planning and implantation failure — excluded. |
| 11 | Monitoring riboflavin transporter deficiency type-2 (RTD-2) — excluded. |
| 12 | Monitoring S-adenosylmethionine therapy — excluded. |
The breadth of this list signals something: Aetna is actively expecting to see these uses come through on claims and is pre-building its denial rationale. Your utilization management team should treat any CPT 83090 claim that doesn't map cleanly to the four covered indications as a likely denial.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Borderline vitamin B12 deficiency (result affects management) | Covered | CPT 83090; ICD-10 D51.x | Must document that result will change management |
| Central retinal vein occlusion with thrombosis history, family history, or age under 56 without arteriosclerotic risk factors | Covered | CPT 83090 | Clinical documentation required; age and risk factor criteria are hard limits |
| Homocystinuria — cystathionine beta synthase deficiency | Covered | CPT 83090; ICD-10 E72.10–E72.19 | Newborn screening only after hypermethioninemia confirmed |
| Idiopathic/recurrent VTE, thrombosis under age 45, or thrombosis at unusual site | Covered | CPT 83090; ICD-10 D68.5x–D68.6x | Age at time of thrombosis must be documented |
| Cardiovascular disease or stroke risk | Not Covered / Experimental | CPT 83090 | See CPB 0381 |
| Cognitive impairment / dementia / Alzheimer's disease | Not Covered / Experimental | CPT 83090 | No coverage regardless of clinical context |
| MTHFR abnormality management | Not Covered / Experimental | CPT 83090 | Explicitly excluded |
| Methotrexate therapy monitoring | Not Covered / Experimental | CPT 83090 | Common rheumatology use — Aetna denies this |
| Recurrent pregnancy loss | Not Covered / Experimental | CPT 83090 | See CPB 0348 |
| Pre-eclampsia risk | Not Covered / Experimental | CPT 83090 | Explicitly listed as unproven biomarker use |
| Depression / suicide risk | Not Covered / Experimental | CPT 83090 | Excluded |
| IVF planning / implantation failure | Not Covered / Experimental | CPT 83090 | Excluded |
| Migraine headaches | Not Covered / Experimental | CPT 83090 | Excluded |
| Multiple sclerosis | Not Covered / Experimental | CPT 83090 | Excluded |
| Erectile dysfunction | Not Covered / Experimental | CPT 83090 | Excluded as biomarker |
| Gastric cancer risk | Not Covered / Experimental | CPT 83090 | Excluded as biomarker |
| RTD-2 monitoring | Not Covered / Experimental | CPT 83090 | Explicitly excluded |
| S-adenosylmethionine therapy monitoring | Not Covered / Experimental | CPT 83090 | Explicitly excluded |
| Autism assessment | Not Covered / Experimental | CPT 83090 | See CPB 0648 |
| Polycystic ovary syndrome | Not Covered / Experimental | CPT 83090; ICD-10 E28.2 | Excluded |
| Premature ovarian failure | Not Covered / Experimental | CPT 83090; ICD-10 E28.310–E28.319 | Excluded |
Aetna Homocysteine Testing Billing Guidelines and Action Items 2025
| # | Action Item |
|---|---|
| 1 | Audit your CPT 83090 claim history before running November 14, 2025 claims. Pull the last 90 days of 83090 submissions to Aetna. Flag any that list cardiovascular risk, Alzheimer's workup, MTHFR management, or methotrexate monitoring as the primary diagnosis. Those are your denial exposure. |
| 2 | Update your charge capture to require an approved ICD-10 before 83090 goes out. CPB 0763 includes 824 ICD-10-CM codes—a hard-stop on a short list of code ranges won't cut it. Pull the full code list directly from CPB 0763 and build your billing system validation against that complete list. Your compliance officer should sign off on the mapping before it goes live. |
| 3 | Educate ordering physicians on the four covered indications. This is especially critical in internal medicine, neurology, and functional medicine practices where homocysteine panels are frequently ordered for cardiovascular or cognitive reasons. Your physicians need to know Aetna homocysteine testing billing now requires specific, narrow clinical justification. |
| 4 | For newborn screening claims specifically, document that hypermethioninemia was confirmed before plasma homocysteine was ordered. Submit that documentation with the claim. Without it, expect a denial. |
| 5 | For central retinal vein occlusion claims, document the member's age at time of presentation and their thrombosis history (personal or family) in the clinical notes. If the patient is under 56 and lacks arteriosclerotic risk factors, document that explicitly. These are the qualifying criteria, and your notes need to match. |
| 6 | Don't submit homocysteine testing billing appeals based on physician preference alone. Aetna's exclusion list is built on evidence reviews. A letter of medical necessity that doesn't tie to one of the four covered indications won't move the needle. Save the appeal resources for claims that have a genuine coverage argument. |
| 7 | If your practice uses homocysteine as a routine panel component, that panel needs a redesign before the effective date of November 14, 2025. A bundled order that includes 83090 alongside other markers will not rescue a non-covered indication. |
CPT and ICD-10 Codes for Homocysteine Testing Under CPB 0763
Covered CPT Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| 83090 | CPT | Homocysteine |
Key ICD-10-CM Diagnosis Codes
The full policy includes 824 ICD-10-CM codes. The table below includes all codes provided in the policy data. Presence on the ICD-10 list does not guarantee coverage — the clinical indication must still match one of the four covered criteria. For precise code descriptions, reference the official ICD-10-CM codebook directly.
| Code | Description |
|---|---|
| C16.0 | Malignant neoplasm of stomach |
| C16.1 | Malignant neoplasm of stomach |
| C16.2 | Malignant neoplasm of stomach |
| C16.3 | Malignant neoplasm of stomach |
| C16.4 | Malignant neoplasm of stomach |
| C16.5 | Malignant neoplasm of stomach |
| C16.6 | Malignant neoplasm of stomach |
| C16.7 | Malignant neoplasm of stomach |
| C16.8 | Malignant neoplasm of stomach |
| C16.9 | Malignant neoplasm of stomach |
| D51.0 | Vitamin B12 deficiency anemia |
| D51.1 | Vitamin B12 deficiency anemia |
| D51.2 | Vitamin B12 deficiency anemia |
| D51.3 | Vitamin B12 deficiency anemia |
| D51.4 | Vitamin B12 deficiency anemia |
| D51.5 | Vitamin B12 deficiency anemia |
| D51.6 | Vitamin B12 deficiency anemia |
| D51.7 | Vitamin B12 deficiency anemia |
| D51.8 | Vitamin B12 deficiency anemia |
| D51.9 | Vitamin B12 deficiency anemia |
| D68.51 | Primary or other thrombophilia |
| D68.52 | Primary or other thrombophilia |
| D68.53 | Primary or other thrombophilia |
| D68.54 | Primary or other thrombophilia |
| D68.55 | Primary or other thrombophilia |
| D68.56 | Primary or other thrombophilia |
| D68.57 | Primary or other thrombophilia |
| D68.58 | Primary or other thrombophilia |
| D68.59 | Primary or other thrombophilia |
| D68.60 | Primary or other thrombophilia |
| D68.61 | Primary or other thrombophilia |
| D68.62 | Primary or other thrombophilia |
| D68.63 | Primary or other thrombophilia |
| D68.64 | Primary or other thrombophilia |
| D68.65 | Primary or other thrombophilia |
| D68.66 | Primary or other thrombophilia |
| D68.67 | Primary or other thrombophilia |
| D68.68 | Primary or other thrombophilia |
| D68.69 | Primary or other thrombophilia |
| D81.818 | Other biotin-dependent carboxylase deficiency |
| D81.819 | Biotin-dependent carboxylase deficiency, unspecified |
| E10.10–E13.9 | Diabetes mellitus |
| E28.2 | Polycystic ovarian syndrome |
| E28.310 | Primary ovarian failure |
| E28.311 | Primary ovarian failure |
| E28.312 | Primary ovarian failure |
| E28.313 | Primary ovarian failure |
| E28.314 | Primary ovarian failure |
| E28.315 | Primary ovarian failure |
| E28.316 | Primary ovarian failure |
| E28.317 | Primary ovarian failure |
| E28.318 | Primary ovarian failure |
| E28.319 | Primary ovarian failure |
| E53.8 | Deficiency of other specified B group vitamins |
| E71.41 | Primary carnitine deficiency |
| E72.10–E72.19 | Disturbances of sulphur-bearing amino-acid metabolism |
| E75.0–E75.8 | GM2 gangliosidosis, other and unspecified gangliosidosis |
| E75.22 | Gaucher disease |
| E75.23 | Krabbe disease |
| E75.25 | Metachromatic leukodystrophy |
| E75.29 | Other sphingolipidosis |
Note: The full policy includes 824 ICD-10-CM codes across multiple condition categories. The codes above represent what was provided in the source policy data. For the complete code list, reference CPB 0763 directly at the Aetna source document. The C16.x gastric cancer codes and E28.x polycystic ovary/ovarian failure codes appear in the policy but map to non-covered indications — their presence in the ICD-10 list likely reflects mapping for denial purposes, not coverage. Confirm with your compliance officer before using those codes with 83090.
Get the Full Picture for CPT 83090
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.